<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03333668</url>
  </required_header>
  <id_info>
    <org_study_id>PCCWUAR</org_study_id>
    <nct_id>NCT03333668</nct_id>
  </id_info>
  <brief_title>Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD Adolescents</brief_title>
  <acronym>AGUALIS</acronym>
  <official_title>Experimental fMRI Study on the Comparison of the Brain Function Effects of a Single Dose of Guanfacine and Lisdexamfetamine Relative to Placebo in Children and Adolescents With ADHD.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is not a clinical trial. The aim of this study is to understand the mechanism of action&#xD;
      of two recently licensed drugs for ADHD on brain function. We will compare the brain&#xD;
      activation changes elicited by Guanfacine extended release (GXR; a non-stimulant drug) with&#xD;
      the brain activation changes elicited by Lisdexamfetamine (LISDEX; a stimulant drug) and by&#xD;
      placebo in 20 drug-free patients with ADHD using functional Magnetic Resonance Imaging&#xD;
      (fMRI). For this purpose we intend to scan participants during their performance of tasks of&#xD;
      attention, working memory, and inhibition, which we know from previous studies to elicit&#xD;
      abnormal brain activation patterns in ADHD patients (Rubia et al., 2005; Smith et al., 2006).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty ADHD patients between 8 and 20 years of age will participate in the double-blind,&#xD;
      randomised, active drug condition, within-group, placebo-controlled experimental fMRI study.&#xD;
      Each participant will be assessed in baseline measures during a pre-assessment visit. Then&#xD;
      the patient will be scanned 3 times under each of these 3 drug conditions: GXR, LISDEX, and&#xD;
      placebo. Every patient will receive a single typical clinical weight-adjusted dose of GXR&#xD;
      (0.05mg/kg rounded down to the closest dose of 1mg, 2mg, or a maximum of 3mg), LISDEX (for&#xD;
      participants aged 8-9 years 20mg regardless of weight; for participants aged 10-20 years the&#xD;
      dose will be calculated at 0.5mg/kg rounded to the closest 30, 40, or 50mg, middle doses,&#xD;
      e.g. 35mg, will be rounded down) and placebo (10mg Vit C) in one of the scans, in a&#xD;
      randomised order. Patients will perform a battery of cognitive tests 3.5 hours after drug&#xD;
      administration, after which the will undergo an fMRI scan. The scan will start 4.5 hours&#xD;
      after drug administration where drugs have shown to have maximum plasma concentration.&#xD;
      Participants will be scanned 3 times, one week apart, under each drug condition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Each participant will complete all three experimental conditions (LISDEX, GXR, placebo) in a randomised order.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in brain activation under the three drug conditions (LISDEX, GXR, placebo)</measure>
    <time_frame>2 weeks (3 hourly scans one week apart)</time_frame>
    <description>Brain activation as measured by blood-oxygen-level-dependent (BOLD) response obtained by fMRI for each of the 3 below listed tasks and functional connectivity measures for the resting state scan.&#xD;
A working memory task (N-back)&#xD;
A tracking stop task&#xD;
A parametric sustained attention task</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in dependent variables extracted from performance on the fMRI tasks used under the three drug conditions (LISDEX, GXR, placebo)</measure>
    <time_frame>2 weeks (3 hourly scans one week apart)</time_frame>
    <description>A working memory task (N-back)&#xD;
A tracking stop task&#xD;
A parametric sustained attention task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in dependent variables extracted from performance on a task battery outside the MRI scanner</measure>
    <time_frame>2 weeks (3 sessions one week apart)</time_frame>
    <description>Gonogo task, Simon task, Continuous performance task, Vigilance task, Time Discrimination task</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>ADHD</condition>
  <arm_group>
    <arm_group_label>Lisdexamfetamine - Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Guanfacine - Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lisdexamfetamine - Guanfacine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisdexamfetamine dimesylate</intervention_name>
    <description>Lisdexamfetamine dimesylate (30mg for smaller, 50mg for larger boys) tablet</description>
    <arm_group_label>Lisdexamfetamine - Guanfacine</arm_group_label>
    <arm_group_label>Lisdexamfetamine - Placebo</arm_group_label>
    <other_name>Vyvanse (Shire Pharmaceuticals Ltd.)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guanfacine Extended Release Oral Tablet</intervention_name>
    <description>Guanfacine Extended Release (0.05mg/kg) tablet</description>
    <arm_group_label>Guanfacine - Placebo</arm_group_label>
    <arm_group_label>Lisdexamfetamine - Guanfacine</arm_group_label>
    <other_name>Intuniv (Shire Pharmaceuticals Ltd.)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vitamin C (10mg) tablet</description>
    <arm_group_label>Guanfacine - Placebo</arm_group_label>
    <arm_group_label>Lisdexamfetamine - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age range: 8-20 years&#xD;
&#xD;
          -  Medication-na√Øve or non-medicated for two weeks or on stimulant medication, and&#xD;
             willing to take the medication off for 48 hours before scans.&#xD;
&#xD;
          -  Meeting DSM-5 diagnosis of ADHD&#xD;
&#xD;
          -  Score above clinical cut-off on the ADHD module of the Kiddie Schedule for Affective&#xD;
             Disorders and Schizophrenia (K-SADS) (Kaufman et al., 1997)&#xD;
&#xD;
          -  Score above clinical cut-off for ADHD on the short forms of the Conners Parent Rating&#xD;
             Scales, CPRS (Conners et al., 2008)&#xD;
&#xD;
          -  Score above cut-off on the ADHD Rating Scale, ADHD-RS (DuPaul, et al., 1998)&#xD;
&#xD;
          -  IQ &gt; 70 as tested on the WASI-II (Wechsler et al., 1999)&#xD;
&#xD;
          -  Mood and depression symptoms will be allowed as long as they are not the primary&#xD;
             diagnosis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  IQ &lt; 70 (Wechsler et al., 1999).&#xD;
&#xD;
          -  Comorbidity with schizophrenia, bipolar disorder, learning disability, OCD, severe&#xD;
             depression with current suicidal behaviour (as assessed by a clinical interview)&#xD;
&#xD;
          -  Neurological problems, i.e. a history of severe neurological illness, e.g. brain&#xD;
             tumour, epilepsy or a history of symptomatic seizures, polyneuropathy etc.&#xD;
&#xD;
          -  Substance abuse history&#xD;
&#xD;
          -  Other illness (cardiovascular, renal, hepatic, metabolic) that would impact the data&#xD;
             integrity or safety of the subject (i.e. contraindicated to any of the treatments) as&#xD;
             determined by the investigators&#xD;
&#xD;
          -  Contraindication to MRI. i.e., previous implantation of metallic material, pacemaker,&#xD;
             implanted medication pumps, neural stimulators, claustrophobia&#xD;
&#xD;
          -  Unable to give informed assent or consent in the case of the parent&#xD;
&#xD;
          -  Contraindications for LISDEX and GXR use (i.e. advanced arteriosclerosis, agitated&#xD;
             states, hyperexcitability, hyperthyroidism, moderate or severe hypertension,&#xD;
             symptomatic cardiovascular disease)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katya Rubia, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katya Rubia, PhD</last_name>
    <phone>02078480463</phone>
    <email>katya.rubia@kcl.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Psychiatry, Psychology &amp; Neuroscience; King's College London</name>
      <address>
        <city>London</city>
        <zip>SE5 8AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katya Rubia, PhD</last_name>
      <phone>02078480463</phone>
      <email>katya.rubia@kcl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Olivia S Kowalczyk, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katya Rubia, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mitul A Mehta, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Rubia K, Smith AB, Brammer MJ, Toone B, Taylor E. Abnormal brain activation during inhibition and error detection in medication-naive adolescents with ADHD. Am J Psychiatry. 2005 Jun;162(6):1067-75.</citation>
    <PMID>15930054</PMID>
  </reference>
  <reference>
    <citation>Smith AB, Taylor E, Brammer M, Toone B, Rubia K. Task-specific hypoactivation in prefrontal and temporoparietal brain regions during motor inhibition and task switching in medication-naive children and adolescents with attention deficit hyperactivity disorder. Am J Psychiatry. 2006 Jun;163(6):1044-51.</citation>
    <PMID>16741205</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 31, 2017</study_first_submitted>
  <study_first_submitted_qc>November 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lisdexamfetamine</keyword>
  <keyword>Guanfacine</keyword>
  <keyword>functional Magnetic Resonance Imaging</keyword>
  <keyword>Attention Deficit Hyperactivity Disorder</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Guanfacine</mesh_term>
    <mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 27, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT03333668/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT03333668/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

